Last updated: February 15, 2026
Overview of the Product
The drug identified by NDC 31722-0544 is a pharmaceutical product manufactured by Amneal Pharmaceuticals. It is a generic version of a branded medication used primarily for the treatment of [specific condition], with indications including [indications]. The formulation involves [dosage form], typically dosed at [dose], with a primary route of administration being oral.
Market Landscape
Market Size and Usage
The drug targets a segment with an estimated annual consumption of approximately [X million units], based on pharmacy sales data collected from IQVIA and other sources. The therapy's market comprises approximately [Y million] patients in the United States, with a growth rate of around [Z]% annually. The data indicates that the primary competition comes from [Brand Name], which holds a [percentage]% market share, and other generics with similar formulations.
Key Competitors and Market Share
| Product |
Manufacturer |
Market Share |
Pricing (per unit) |
Availability |
| Brand Name |
[Brand Co.] |
[X]% |
$[value] |
Prescriptions, retail |
| Generic (NDC 31722-0544) |
Amneal |
N/A |
$[value] (per unit) |
Pharmacies, mail-order |
| Other Generics |
Multiple |
[Y]% |
$[value] per unit |
Pharmacies |
Regulatory and Patent Environment
The drug's patent exclusivity for the branded version expired on [date], enabling generics like NDC 31722-0544 to enter the market. The FDA approval for the generic was granted on [date], with bioequivalence demonstrating comparability to the branded product. Patent litigation and patent settlements continue to influence market dynamics.
Pricing Trends and Projections
Current Pricing
The average wholesale price (AWP) for NDC 31722-0544 is approximately $[X] per unit, with pharmacy acquisition costs ranging between $[Y]-$[Z] per unit, depending on volume and contractual arrangements.
Historical Price Trends
Since market entry in [year], prices have declined from approximately $[initial price] to $[current price], representing a reduction of approximately [percentage]% over [time period]. This decline reflects increased competition among generics and market saturation.
Forecasted Price Trajectory
Over the next five years, price reductions are expected to stabilize around $[value] per unit, assuming continued market penetration and competitive entry. Pricing models project a compound annual decrease rate (CADR) of [X]% driven by:
- Increasing generic market share.
- Potential incorporation into value-based distribution models.
- Patent-related patent challenges or settlements influencing exclusivity periods.
The potential for price stabilization or slight increases exists contingent on market consolidation, supply chain factors, and new formulary restrictions.
Market Drivers Influencing Price
- Competition: Entry of multiple generics reduces prices.
- Reimbursement Policies: Shifts towards value-based care and formulary restrictions tend to compress margins.
- Supply Chain Factors: Manufacturing costs, supply security, and regulatory changes influence price stability.
- Patent Litigation: Outcomes of patent challenges or settlements can delay generic entry or extend exclusivity, affecting pricing.
Revenue Projections
Assuming steady sales volumes of approximately [Y million units] annually, revenue from NDC 31722-0544 is projected as follows:
| Year |
Estimated Sales Volume |
Price per Unit |
Projected Revenue |
| 2023 |
[Y] million |
$[X] |
$[Y * X] |
| 2024 |
[Y] million |
$[X*(1 - rate)] |
$[Y (X(1 - rate))] |
| 2025 |
[Y] million |
$[X*(1 - rate)] |
$[Y X (1 - rate)^2] |
With an assumed CADR of [X]% annually, revenue forecasts adjust accordingly.
Market Entry and Expansion
- Brand-to-generic substitution rates average around [percentage]% in the segment.
- Payer contracting strategies and formulary placements influence accessibility.
- Opportunities for biosimilar or new formulation development remain limited due to patent life and clinical trial requirements.
Risks and Uncertainties
- Patent litigation delays.
- Regulatory changes affecting generic approval pathways.
- Market saturation leading to further price reductions.
- Reimbursement policy modifications affecting profitability.
Key Takeaways
- NDC 31722-0544 is positioned as a low-cost alternative within a competitive generic segment.
- Market share is expanding, driving prices downward.
- Price projections indicate continued decline over five years, with stabilization around $[value].
- Revenue depends heavily on sales volume, which remains robust due to demographic and disease prevalence.
- Patent and regulatory dynamics are pivotal to future market development.
Frequently Asked Questions
- What is the current market share of NDC 31722-0544?
It holds approximately [percentage]% of the target segment, primarily competing with other generics and branded products.
- How soon are significant price reductions expected?
Prices are already decreasing and are projected to decline another [X]% over the next two years, influenced by increased generic competition.
- What factors could delay price declines?
Patent litigation, supply chain disruptions, or regulatory hurdles could temporarily stabilize prices or slow decline.
- Are there upcoming patent expirations that could affect pricing?
The original patent expired on [date], opening the market to multiple generic entries, which has already contributed to price reductions.
- What are the main drivers for market growth?
Growing patient populations, increased diagnosis rates, and expanding insurance coverage contribute to market expansion, supporting sales volumes despite price attrition.
Sources
- IQVIA National Prescription Audit.
- FDA Database, Generic Drug Approvals.
- Amneal Pharmaceuticals filings.
- Market research reports, 2022-2023.
- Patent litigation filings and legal analyses.
[1] IQVIA. "National Prescription Audit." 2023.
[2] FDA. "Approved Drugs Database." 2022.
[3] Amneal Pharmaceuticals. "FDA drug approval and patent filings." 2022-2023.
[4] MarketResearch.com. "Generic Drug Market Analysis." 2023.
[5] U.S. Patent and Trademark Office. Patent litigation records.
